Business Description
Genelux Corporation is a clinical-stage company developing virus-based cancer treatments aimed at patients with hard-to-treat solid tumors. Its primary drug candidate, Olvi-Vec, is a modified vaccinia virus being studied as a treatment for ovarian cancer. The company also maintains a broad library of engineered viral therapies and a proprietary research platform used to discover and develop new treatments. Through a licensing agreement with Newsoara BioPharma, Olvi-Vec is being advanced across Greater China for diagnostic and therapeutic use.
